{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:36:10Z","timestamp":1785771370894,"version":"3.56.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1097\/01.jcp.0000096248.95165.ac","type":"journal-article","created":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T07:31:58Z","timestamp":1069140718000},"page":"646-651","source":"Crossref","is-referenced-by-count":4,"title":["Sertraline in Panic Disorder: Initial Treatment Versus Switch Strategy"],"prefix":"10.1097","volume":"23","author":[{"given":"Matig R.","family":"Mavissakalian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","first-page":"10","article-title":"Management of non-response and intolerance: switching strategies.","volume":"61","author":"Fava","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4088\/JCP.v61n0602","article-title":"Partial response, non-response, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current \u201cnext step\u201d practices.","volume":"61","author":"Fredman","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archpsyc.59.3.233","article-title":"Double blind switch study of imipramine or sertraline treatment of anti\u2013depressant-resistant chronic depression.","volume":"59","author":"Thase","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0924-9338(97)83297-X","article-title":"Reliability and validity of the MINI international neuropsychiatric interview (M.I.N.I): according to the SCID-P.","volume":"12","author":"Sheehan","year":"1997","journal-title":"European Psychiatry"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0006-3223(97)00376-4","article-title":"Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.","volume":"43","author":"Mavissakalian","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/archpsyc.56.9.821","article-title":"Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.","volume":"56","author":"Mavissakalian","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1176\/ajp.152.5.673","article-title":"Imipramine in panic disorder with agoraphobia: dose ranging and plasma level-response relationships.","volume":"152","author":"Mavissakalian","year":"1995","journal-title":"Am J Psychiatry"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.173.1.54","article-title":"Sertraline in the treatment of panic disorder.","volume":"173","author":"Londborg","year":"1998","journal-title":"Br J Psychiatry"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0022-3956(93)90050-C","article-title":"Imipramine treatment of panic disorder with agoraphobia: the second time around.","volume":"27","author":"Mavissakalian","year":"1993","journal-title":"J Psychiatry Res"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0005-7967(79)90041-X","article-title":"Brief standard self-rating for phobic patients.","volume":"17","author":"Marks","year":"1979","journal-title":"Behav Res Ther"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression.","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"R15-13-20210128","first-page":"163","article-title":"Effect size as a measure of symptom-specific drug change on clinical trials.","volume":"29","author":"Leon","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.v61n1206","article-title":"Sertraline treatment of panic disorder: Response in patients at risk for poor outcome.","volume":"61","author":"Pollack","year":"2000","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.jcp.0000096248.95165.ac","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:43:38Z","timestamp":1785768218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200312000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000096248.95165.ac","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}